Clearpoint Neuro, Inc. (CLPT) — SEC Filings
Clearpoint Neuro, Inc. (CLPT) — 28 SEC filings. Latest: 8-K (Nov 20, 2025). Includes 10 8-K, 6 10-Q, 5 SC 13G/A.
View Clearpoint Neuro, Inc. on SEC EDGAR
Overview
Clearpoint Neuro, Inc. (CLPT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: ClearPoint Neuro, Inc. (CLPT) reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased to $8.861 million from $8.122 million in the prior year, driven by a significant rise in service and other revenue to $3.500 milli
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 23 neutral, 2 mixed. The dominant filing sentiment for Clearpoint Neuro, Inc. is neutral.
Filing Type Overview
Clearpoint Neuro, Inc. (CLPT) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 1 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of CLPT's 19 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $8.861M |
| Net Income | -$5.891M |
| EPS | -$0.21 |
| Debt-to-Equity | 2.80 |
| Cash Position | $38.221M |
| Operating Margin | -59.5% |
| Total Assets | $60.357M |
| Total Debt | $29.972M |
Key Executives
- Joseph M. Burnett
- Dr. Steven J. Shagan
- Ms. Jennifer L. Johnson
Industry Context
ClearPoint Neuro operates in the specialized field of minimally invasive neurosurgery, focusing on navigation and robotic-assisted procedures. The industry is characterized by rapid technological advancements, a high degree of regulatory oversight (FDA), and a need for significant R&D investment. Key trends include the increasing adoption of robotic surgery, demand for improved patient outcomes, and the integration of AI and advanced imaging in surgical planning and execution.
Top Tags
medical-devices (5) · Medical Devices (4) · corporate-governance (3) · 10-Q (3) · financials (3) · material-definitive-agreement (3) · ClearPoint Neuro (3) · corporate-action (2) · 10-K (2) · amendment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue (Q3 2025) | $8.861M | Increased from $8.122M in Q3 2024 |
| Total Revenue (YTD Q3 2025) | $26.561M | Increased from $23.619M in YTD Q3 2024 |
| Net Loss (Q3 2025) | $5.891M | Widened from $4.974M in Q3 2024 |
| Net Loss (YTD Q3 2025) | $17.754M | Widened from $13.528M in YTD Q3 2024 |
| Accumulated Deficit | $209.1M | As of September 30, 2025, indicating significant historical losses |
| Cash used in operations (YTD Q3 2025) | $11.8M | Increased from $7.707M in YTD Q3 2024 |
| Cash and Cash Equivalents | $38.221M | As of September 30, 2025, up from $20.104M at Dec 31, 2024 |
| Net proceeds from note payable | $28.7M | Received in May 2025 from 2025 NPA |
| Net proceeds from common stock offering | $3.3M | Received in May 2025 from 2025 SPA |
| Biologics and drug delivery customers | 60+ | Evaluating or using products/services in trials |
| Total Revenue | $7.5M | Increased 21% from $6.2M in Q2 2024 to $7.5M in Q2 2025 |
| Net Loss | $10.2M | Widened from $8.5M in Q2 2024 to $10.2M in Q2 2025 |
| Neurosurgery Navigation and Therapy Disposable Products Revenue Growth | 25% | Increased to $5.0M in Q2 2025 |
| Biologics and Drug Delivery Services and License Fees Revenue Growth | 14% | Increased to $2.5M in Q2 2025 |
| Research and Development Expense | $4.2M | Increased 20% in Q2 2025 |
Frequently Asked Questions
What are the latest SEC filings for Clearpoint Neuro, Inc. (CLPT)?
Clearpoint Neuro, Inc. has 28 recent SEC filings from Jan 2024 to Nov 2025, including 10 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLPT filings?
Across 28 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 23 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Clearpoint Neuro, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Clearpoint Neuro, Inc. (CLPT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Clearpoint Neuro, Inc.?
Key financial highlights from Clearpoint Neuro, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CLPT?
The investment thesis for CLPT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Clearpoint Neuro, Inc.?
Key executives identified across Clearpoint Neuro, Inc.'s filings include Joseph M. Burnett, Dr. Steven J. Shagan, Ms. Jennifer L. Johnson.
What are the main risk factors for Clearpoint Neuro, Inc. stock?
Of CLPT's 19 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Clearpoint Neuro, Inc.?
Forward guidance and predictions for Clearpoint Neuro, Inc. are extracted from SEC filings as they are enriched.